Development of Chitosan-based Dry Powder Inhalation System of Cisplatin for Lung Cancer

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Oncology

Background:

• Cisplatin is a platinum compound used to treat non-small cell lung cancer by inhibiting DNA replication and transcription.
• Direct lung delivery aims to localize chemotherapy, enhancing efficacy and reducing systemic toxicity.

Purpose of the Study:

• To develop and characterize cisplatin-loaded chitosan microspheres for direct pulmonary administration.
• To evaluate the in vitro performance and stability of these microparticulate systems for sustained drug release.

Main Methods:

• Cisplatin-loaded chitosan microspheres were prepared using emulsification and ionotropic gelation.
• Characterization included drug content, particle size, flow properties, SEM, and in vitro release studies in simulated lung fluid.
• Fine particle fraction (FPF) was assessed using a twin-stage impinger (TSI).

Main Results:

• The study successfully prepared and characterized cisplatin-loaded chitosan microspheres.
• In vitro release studies demonstrated sustained drug release at physiological conditions (37°C, pH 7.4).
• The formulation exhibited favorable characteristics for respirable delivery and stability under various storage conditions.

Conclusions:

• Cisplatin-loaded chitosan microspheres are a promising system for direct lung delivery in non-small cell lung cancer treatment.
• This approach facilitates localized and sustained drug action, potentially improving therapeutic efficacy.
• Further in vivo studies are warranted to confirm the clinical benefits of this novel drug delivery system.